Manufacturer
257 recalls in our database name Hospira, Inc. as the manufacturing or recalling firm.
Of the 257 recalls from Hospira, Inc. we have scored against our rubric, 18 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 104 (40%) are Severe.
Which agencies issued them
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Hospira Inc. is recalling 681,400 vials of Ondansetron Injection because glass spicules were found during a site inspection.
Hospira Inc. is recalling 251,400 vials of Metoclopramide Injection because glass spicules were found during a site inspection.
Hospira is recalling 43,840 GemStar infusion pumps worldwide because pressure sensor calibration drift may cause the device to fail occlusion tests or issue false alarms.
Hospira is recalling GemStar infusion pumps because pressure sensor calibration drift may cause the device to fail occlusion tests or report false errors.
Hospira is recalling 59 Symbiq infuser batteries because the wrong model (E10) was shipped instead of the correct E09 model.
Hospira is recalling 71 Plum A+ Infusion Pumps because pressure sensor calibration drift can cause false alarms or missed occlusions.
Hospira is recalling 7,691 Plum A+ Infusion Pumps because pressure sensor calibration drift may cause false alarms or undetected occlusions.
Hospira is recalling 214 Plum A+3 Infusion Systems because a pressure sensor pin may break, potentially preventing the detection of line occlusions.
Hospira is recalling 10,669 Plum A+ Infusion Systems because the distal pressure sensor pin may break. This defect can prevent the device from detecting occlusions in the administration set.
Hospira is recalling 179 Plum A+ Hyperbaric Infusion Pumps because distal pressure sensor calibration drift may cause false alarms or occlusions.
Hospira Inc. is recalling 182,971 Plum A+ Infusion Systems because a distal pressure sensor pin may break, potentially preventing the detection of line occlusions.
Hospira is recalling Plum A+ Infusion Pumps because pressure sensor calibration drift may cause false occlusion alarms or missed occlusions.
Hospira is recalling 71 Plum A+ Infusion Systems because a pressure sensor pin may break, potentially preventing the detection of line occlusions.
Hospira is recalling 182,970 Plum A+ Infusion Pumps because pressure sensor calibration drift may cause false alarms or missed occlusions.
Hospira Inc. is recalling Plum A+ Infusion Systems because the distal pressure sensor pin may break, potentially preventing the detection of line occlusions.
Hospira recalled 10,669 Plum A+ infusion pumps after reports of distal pressure sensor calibration drift. The issue may cause false occlusion alarms or distal occlusions.
Hospira Inc. is recalling 179 Plum A+ Hyperbaric Infusion Systems because the distal pressure sensor pin may break, potentially preventing the detection of line occlusions.
Hospira is recalling 7,692 Plum A+3 Infusion Systems because a pressure sensor pin may break, potentially preventing the detection of line occlusions.
Hospira is recalling 21,551 Plum A+3 Infusion Systems because a distal pressure sensor pin may break, potentially preventing the detection of line occlusions.
Hospira is recalling 214 Plum A+3 Infusion Pump Systems because distal pressure sensor calibration drift may cause false alarms or occlusions.
Hospira Inc. is recalling 70,450 vials of Propofol Injectable Emulsion because visible particles were found in the glass during inspection.
Hospira is recalling 187,150 vials of Bupivacaine Hydrochloride with Epinephrine due to a lack of assurance of sterility and potential vial breakage.
Hospira is recalling 86,400 ampuls of 5% Lidocaine HCl and 7.5% Dextrose Injection due to reports of visible particulates in the glass ampules.
Hospira Inc. is recalling 283,150 vials of Propofol Injectable Emulsion because visible particulate matter was found embedded in the glass vials during inspection.
Hospira is recalling 264,432 bags of 0.9% Sodium Chloride Injection because the product may contain fibrous material.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
Hospira
American pharmaceutical company
Source: Wikidata (Q1470525), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.